Foresite Capital Management Iv, LLC Lyell Immunopharma, Inc. Transaction History
Foresite Capital Management Iv, LLC
- $153 Million
- Q3 2024
A detailed history of Foresite Capital Management Iv, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Foresite Capital Management Iv, LLC holds 8,325,000 shares of LYEL stock, worth $9.16 Million. This represents 7.51% of its overall portfolio holdings.
Number of Shares
8,325,000
Previous 8,325,000
-0.0%
Holding current value
$9.16 Million
Previous $12.1 Million
4.83%
% of portfolio
7.51%
Previous 8.11%
Shares
5 transactions
Others Institutions Holding LYEL
# of Institutions
122Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$22.2 Million30.81% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$16.6 Million13.96% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$16.6 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$11.1 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $273M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...